Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
30.23
-1.81 (-5.65%)
At close: Apr 15, 2025, 4:00 PM
29.97
-0.26 (-0.87%)
Pre-market: Apr 16, 2025, 4:24 AM EDT
Vaxcyte Employees
Vaxcyte had 414 employees as of December 31, 2024. The number of employees increased by 160 or 62.99% compared to the previous year.
Employees
414
Change (1Y)
160
Growth (1Y)
62.99%
Revenue / Employee
n/a
Profits / Employee
-$1,120,597
Market Cap
3.89B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 414 | 160 | 62.99% |
Dec 31, 2023 | 254 | 96 | 60.76% |
Dec 31, 2022 | 158 | 69 | 77.53% |
Dec 31, 2021 | 89 | 31 | 53.45% |
Dec 31, 2020 | 58 | 15 | 34.88% |
Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
PCVX News
- 15 days ago - Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity - Seeking Alpha
- 15 days ago - Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Benzinga
- 15 days ago - Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - GlobeNewsWire
- 16 days ago - Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - GlobeNewsWire
- 7 weeks ago - Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewsWire
- 2 months ago - Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - GlobeNewsWire